Research Article
MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes
Table 2
Survival analysis of miRSNPs in mTOR pathway in 146 patients with limited-disease small cell lung cancer.
| Gene SNP | Model | 5yOS | HR (95% CI) | Log-rank | HR (95% CI) (adjusted) | adjusted | |
| VEGFA rs10434 | DOM | GG (100) | 39.0% | 0.768 (0.449–1.314) | 0.334 | 0.864 (0.498–1.497) | 0.601 | 0.651 | GA + AA (46) | 39.7% | DDIT4 rs1053639 | DOM | AA (87) | 34.0% | 0.949 (0.577–1.560) | 0.835 | 0.910 (0.553–1.498) | 0.712 | 0.688 | AT + TT (59) | 44.8% | MAPK1 rs1063311 | DOM | CC (107) | 36.6% | 0.637 (0.338–1.199) | 0.158 | 0.546 (0.288–1.037) | 0.064 | 0.165 | CT + TT (36) | 45.8% | PTEN rs11202607 | ADD | CC (122) | 37.2% | 0.714 (0.325–1.570) | 0.400 | 0.596 (0.267–1.331) | 0.207 | 0.391 | CT (23) | 55.1% | PIK3R1 rs12755 | REC | CA + CC (134) | 28.7% | 0.508 (0.284–0.909) | 0.107 | 0.225 (0.054–0.931) | 0.040 | 0.129 | AA (11) | 55.7% | MTOR rs2536 | ADD | TT (117) | 43.4% | 1.838 (1.033–3.272) | 0.036 | 1.948 (1.090–3.482) | 0.024 | 0.103 | TC (25) | 22.9% | VEGFA rs3025039 | DOM | CC (89) | 42.3% | 1.025 (0.617–1.705) | 0.923 | 1.083 (0.639–1.837) | 0.767 | 0.704 | CT + TT (55) | 35.1% | PIK3R1 rs3756668 | REC | GA + GG (119) | 35.5% | 0.417 (0.190–0.916) | 0.025 | 0.388 (0.176–0.856) | 0.019 | 0.103 | AA (25) | 47.7% | PTEN rs701848 | DOM | TT (52) | 30.2% | 0.802 (0.472–1.363) | 0.413 | 0.725 (0.420–1.252) | 0.249 | 0.435 | TC + CC (92) | 41.9% |
|
|
Adjusted for age, gender, Karnofsky performance score (KPS), smoking history, and Charlson comorbidity index (CCI). miRSNPs: miRNA-related single nucleotide polymorphisms; OS: overall survival; HR: hazard ratio; CI: confidence interval. Reference sequences: VEGFA GenBank NG_008732; DDIT4 GenBank NM_019058; MAPK1 GenBank NG_023054; PTEN GenBank NG_007466; PIK3R1 GenBank NG_012849; MTOR GenBank NG_033239.
|